Epidemiology and Pathogenesis of Myelodysplastic Syndrome
暂无分享,去创建一个
A. Zeidan | R. Shallis | Lara K. Rotter | S. Shimony | K. Ling | Maximilian F. Stahl | E. Chen | M. Stahl
[1] D. Neuberg,et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. , 2022, NEJM evidence.
[2] A. Wei,et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. , 2022, The Lancet. Haematology.
[3] G. Garcia-Manero,et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes , 2022, American journal of hematology.
[4] Weili Cai,et al. The Biological and Clinical Consequences of RNA Splicing Factor U2AF1 Mutation in Myeloid Malignancies , 2022, Cancers.
[5] A. Zeidan,et al. CHIPing away the progression potential of CHIP: A new reality in the making. , 2022, Blood reviews.
[6] H. Deeg,et al. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] K. Metzeler,et al. Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome. , 2022, Journal of Clinical Oncology.
[8] W. Liu,et al. In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2 , 2022, Leukemia.
[9] T. Bowman,et al. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations , 2022, bioRxiv.
[10] S. Gore,et al. Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis , 2022, Leukemia & lymphoma.
[11] P. D. Dal Cin,et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML , 2022, Blood advances.
[12] Somnath Ghosal,et al. DNA methylation: a saga of genome maintenance in hematological perspective , 2022, Human Cell.
[13] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[14] L. Abrahmsén,et al. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ) , 2021, Nature Communications.
[15] E. Clappier,et al. Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group , 2021, Blood.
[16] D. Neuberg,et al. Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study , 2021, Blood.
[17] M. Troadec,et al. TP53 in Myelodysplastic Syndromes , 2021, Cancers.
[18] D. Tiblalexi,et al. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome , 2021, Blood advances.
[19] Yosuke Tanaka,et al. A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. , 2021, Cell reports.
[20] Z. Ge,et al. Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis , 2021, Frontiers in Pharmacology.
[21] I. Flinn,et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms , 2021, Leukemia.
[22] H. Kantarjian,et al. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes , 2021, Cancer.
[23] M. Konopleva,et al. Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). , 2021 .
[24] L. Nezi,et al. TERT promoter mutations and melanoma survival: a comprehensive literature review and meta-analysis. , 2021, Critical reviews in oncology/hematology.
[25] T. Haferlach,et al. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms. , 2020, Blood cancer discovery.
[26] Benjamin L. Ebert,et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.
[27] S. Carr,et al. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML , 2020, JCI insight.
[28] Wan-Jen Hong,et al. Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study , 2020 .
[29] E. Vellenga,et al. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Cazzola. Myelodysplastic Syndromes. , 2020, The New England journal of medicine.
[31] M. Mukherji,et al. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia , 2020, Communications biology.
[32] A. Viale,et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2020, Nature Medicine.
[33] P. Campbell,et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS , 2020, Blood.
[34] P. Glazer,et al. Oncometabolites suppress DNA repair by disrupting local chromatin signalling , 2020, Nature.
[35] B. Shuch,et al. Oncometabolites suppress DNA repair by disrupting local chromatin signaling , 2020, Nature.
[36] P. Campbell,et al. SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). , 2020, Blood.
[37] L. Gondek,et al. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. , 2020, Blood advances.
[38] R. Collins,et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. , 2020, The Lancet. Haematology.
[39] P. Vyas,et al. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications , 2020, Leukemia.
[40] L. Shih,et al. DNMT3A mutants provide proliferating advantage with augmentation of self-renewal activity in the pathogenesis of AML in KMT2A-PTD-positive leukemic cells , 2020, Oncogenesis.
[41] M. Cazzola,et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.
[42] Dannie Durand,et al. Family , 2006, Death in the Modern World.
[43] Jie Jin,et al. Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes. , 2020, American journal of cancer research.
[44] H. Kantarjian,et al. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia , 2019, Cancer.
[45] Y. Shyr,et al. The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2019, Blood.
[46] T. Stricker,et al. Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition , 2019, Blood.
[47] B. Ebert,et al. Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS , 2019, Leukemia & lymphoma.
[48] B. Ebert,et al. Clonal hematopoiesis in human aging and disease , 2019, Science.
[49] M. Gounder,et al. METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours , 2019, Annals of Oncology.
[50] B. Ebert,et al. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[51] N. Hosono. Genetic abnormalities and pathophysiology of MDS , 2019, International Journal of Clinical Oncology.
[52] FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation , 2019, Case Medical Research.
[53] K. Pradhan,et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies , 2019, Nature Cell Biology.
[54] A. Ashworth,et al. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers , 2019, Nature Communications.
[55] Xiaomei Ma,et al. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. , 2019, Blood reviews.
[56] P. Fenaux,et al. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. , 2019, Blood.
[57] S. Jaiswal,et al. Clonal hematopoiesis: Pre‐cancer PLUS , 2019, Advances in cancer research.
[58] Jiqiang Yao,et al. Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) , 2018, Blood.
[59] D. Steensma. Clinical consequences of clonal hematopoiesis of indeterminate potential. , 2018, Blood advances.
[60] A. Shilatifard,et al. TET2 coactivates gene expression through demethylation of enhancers , 2018, Science Advances.
[61] Y. Xiong,et al. SNIP1 Recruits TET2 to Regulate c-MYC Target Genes and Cellular DNA Damage Response , 2018, Cell reports.
[62] R. Ohgami,et al. del (5q) solely in Myelodysplastic syndrome , 2018, Atlas of Genetics and Cytogenetics in Oncology and Haematology.
[63] B. Ebert,et al. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. , 2018, Cancer cell.
[64] M. Walter,et al. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. , 2018, Cancer research.
[65] M. Warmuth,et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers , 2018, Nature Medicine.
[66] C. Shao,et al. The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. , 2018, Molecular cell.
[67] J. Maciejewski,et al. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors , 2018, Clinical Cancer Research.
[68] Kenneth D. Doig,et al. ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach , 2017, Blood Cancer Journal.
[69] Kenneth D. Doig,et al. ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach , 2017, Blood Cancer Journal.
[70] R. Wells,et al. Tet2 restrains inflammatory gene expression in macrophages. , 2017, Experimental hematology.
[71] O. Abdel-Wahab,et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression , 2017, Cell.
[72] R. Deberardinis,et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis , 2017, Nature.
[73] Q. Song,et al. Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells , 2017, Scientific Reports.
[74] M. Cazzola,et al. Clinical significance of somatic mutation in unexplained blood cytopenia. , 2017, Blood.
[75] T. Graubert,et al. Functions of Replication Protein A as a Sensor of R Loops and a Regulator of RNaseH1. , 2017, Molecular cell.
[76] D. Neuberg,et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.
[77] Gregory A. Breuer,et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.
[78] B. Ebert,et al. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.
[79] M. Warmuth,et al. H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies , 2016 .
[80] B. Dumitriu,et al. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS , 2016, British journal of haematology.
[81] R. Bellazzi,et al. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[83] S. Nahas,et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.
[84] L. Abrahmsén,et al. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy , 2016, Front. Oncol..
[85] W. Wodzig,et al. Ascorbic acid serum levels are reduced in patients with hematological malignancies , 2016, Results in immunology.
[86] H. Kantarjian,et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression , 2015, Leukemia.
[87] P. Campbell,et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.
[88] B. Ebert,et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.
[89] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[90] Kim Nasmyth,et al. Closing the cohesin ring: Structure and function of its Smc3-kleisin interface , 2014, Science.
[91] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[92] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] Lili Yang,et al. Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes. , 2014, Leukemia research.
[94] Christopher A. Miller,et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. , 2014, Cancer cell.
[95] A. Grinberg,et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis , 2014, Nature Medicine.
[96] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[97] M. Cazzola,et al. The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.
[98] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[99] Sanjeeva Srivastava,et al. Cohesin: Functions beyond sister chromatid cohesion , 2013, FEBS letters.
[100] Y. Xiong,et al. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. , 2013, Cancer cell.
[101] Masao Nagasaki,et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms , 2012, Nature Genetics.
[102] L. Rushton,et al. Myelodysplastic Syndrome and Benzene Exposure Among Petroleum Workers: An International Pooled Analysis , 2012, Journal of the National Cancer Institute.
[103] Iannis Aifantis,et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.
[104] I. Weissman,et al. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.
[105] P. Hieter,et al. Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators , 2012, PLoS genetics.
[106] Zhimin Chen,et al. Human telomerase reverse transcriptase transfection reduces apoptosis in human penile smooth muscle cells and slows down cellular aging. , 2012, The journal of sexual medicine.
[107] A. Tefferi,et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.
[108] Peter J Campbell,et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.
[109] M. Björkholm,et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] P. Opolon,et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.
[111] O. Abdel-Wahab,et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.
[112] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[113] C. Cogle,et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. , 2011, Blood.
[114] B. Quesnel,et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.
[115] Benjamin L Ebert,et al. Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] D. Preston,et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] R. Arceci. Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes , 2011 .
[118] M Cazzola,et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.
[119] M. Cazzola,et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia , 2010, Leukemia.
[120] T. Economopoulos,et al. Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS) , 2010, Annals of Hematology.
[121] D. Birnbaum,et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.
[122] Sui Huang. Faculty Opinions recommendation of An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. , 2009 .
[123] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[124] I. Weissman,et al. CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.
[125] W. Hahn,et al. An RNA dependent RNA polymerase formed by hTERT and the RNase MRP RNA , 2009, Nature.
[126] Federica Briatore,et al. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes , 2009, Cancer biology & therapy.
[127] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[128] C. O'keefe,et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. , 2009, Blood.
[129] A. Tefferi,et al. Myelodysplastic syndromes. , 2009, The New England journal of medicine.
[130] J. Shay,et al. Actions of human telomerase beyond telomeres , 2008, Cell Research.
[131] E. Andreakos,et al. Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes , 2007, Clinical Cancer Research.
[132] Victor V Lobanenkov,et al. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene , 2007, Nucleic acids research.
[133] F. Askin,et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. , 2007, Blood.
[134] J. Herman,et al. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. , 2007, Cancer research.
[135] J. Rutka,et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] R. Humphries,et al. Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family. , 2006, Gene.
[137] M. Blasco. Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.
[138] W. Hahn,et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[139] E. Estey,et al. Risk factors of myelodysplastic syndromes: a case–control study , 2005, Leukemia.
[140] M. Valentine,et al. Telomerase expression predicts unfavorable outcome in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[141] K. Flanders,et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. , 2004, The New England journal of medicine.
[142] Axel Hoos,et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] H. Kreipe,et al. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. , 2004, Leukemia research.
[144] H. K. Jeon,et al. Ectopic Expression of the Catalytic Subunit of Telomerase Protects against Brain Injury Resulting from Ischemia and NMDA-Induced Neurotoxicity , 2004, The Journal of Neuroscience.
[145] F. Bosman,et al. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity , 2002, International journal of cancer.
[146] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[147] C. Preudhomme,et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France , 2001, British journal of haematology.
[148] G. Mufti,et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.
[149] R. Weinberg,et al. Methylation of the human telomerase gene CpG island. , 2000, Cancer research.
[150] R. Davis,et al. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. , 1998, Leukemia research.
[151] T. Hirano,et al. Identification of Xenopus SMC protein complexes required for sister chromatid cohesion. , 1998, Genes & development.
[152] P. Venugopal,et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. , 1996, International journal of hematology.
[153] H. Preisler,et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis , 1995, American journal of hematology.